Send to

Choose Destination
See comment in PubMed Commons below
Curr Oncol. 2011 Aug;18(4):180-90.

Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey.

Author information

  • 1University of Toronto and Sunnybrook Health Sciences Centre, Toronto, ON.


Triple-negative breast cancer (TNBC) has a poor prognosis compared to other subtypes and lacks common therapeutic targets, including HER 2 and the estrogen and progesterone receptors. The clinicopathological heterogeneity of the disease and limited treatment options make clinical management particularly challenging. Here we present the results of a survey of Canadian clinical oncologists regarding treatment of TNBC, and review recent and ongoing clinical research in this area. Our survey results show that the majority of respondents use a combination of anthracyclines-taxanes as adjuvant therapy for early TNBC. For the first-line treatment of metastatic TNBC, most clinicians recommend taxanes, while single agent capecitabine and platinum-based therapies are more common for subsequent lines of therapy. Despite the ongoing development of novel targeted therapies, chemotherapy remains the mainstay of treatment for TNBC.


Triple-negative; basal-like; breast neoplasms; cancer treatment; chemotherapy; clinical opinion; clinical research; targeted therapy

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Multimed Inc. Icon for PubMed Central
    Loading ...
    Write to the Help Desk